D2R | DNA to RNA is a research initiative at McGill University taking an inclusive Canadian approach to developing genomic-based #RNA therapies for rare diseases, infectious diseases and cancer. www.mcgill.ca/dna-to-rna/ www.youtube.com/@D2RMcGillhttps://bsky.app/profile/d2rmcgill.bsky.socialhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3ms6ynnasbs2e📢 New funding opportunity The D2R Strategic Initiative on Cancer Vaccines will support multidisciplinary teams advancing neoantigen-based cancer vaccines toward clinical implementation, including first-in-human studies. 📅 LOI deadline: Sept. 1, 2026 (9 a.m. ET) 🔗 https://www.mcgill.ca/dna-to-rna/funding/funding-opportunities/strategic-initiative-cancer-vaccines03 Aug 2026 17:13 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3ms6ynnasbs2ehttps://bsky.app/profile/d2rmcgill.bsky.social/post/3mq7se7cozy26🔊 #D2RProjectSpotlight: mRNA therapy for CLN3 Batten disease led by Professor Carl Ernst (@mcgillu) 🔗 Learn more here: buff.ly/yELbB3f09 Jul 2026 14:02 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mq7se7cozy26https://bsky.app/profile/d2rmcgill.bsky.social/post/3mq2rohdkgx2l🔊 #D2RProjectSpotlight: From Bench to Bedside: RNA and AAV Gene Therapies for Diffuse Midline Gliomas led by Professor Nada Jabado (@mcgillu) 🔗 Learn more here: buff.ly/GtdyVpA07 Jul 2026 14:07 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mq2rohdkgx2lhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3mpj67moy2u2v🔊 #D2RProjectSpotlight: LNP/mRNA Therapy for Sickle Cell Disease led by Professor Anastasia Nijnik (@mcgillu) 🔗 Learn more here: buff.ly/ezQMPOB30 Jun 2026 14:03 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mpj67moy2u2vhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3mp4lz5yzky2r#D2RTraineeSpotlight ✨ Trainee Spotlight: Michael Trinh (@McGillU) 👉 Read the full interview to learn more about Michael’s journey and research: buff.ly/Hi9WRgf25 Jun 2026 14:06 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mp4lz5yzky2rhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3moxl4axpfl23🔊 #D2RProjectSpotlight: From Trial to Gene Therapy: Restoring Differentiation in IDH-Mutant Glioma led by Professor Charles Couturier (@mcgillu) 🔗 Learn more here: buff.ly/OiMiCTi23 Jun 2026 14:06 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3moxl4axpfl23https://bsky.app/profile/d2rmcgill.bsky.social/post/3moiligkx2s2m#D2RTraineeSpotlight ✨ Trainee Spotlight: Kate Bornais (@McGillU)👉 Read the full interview to learn more about Kate’s journey and research: buff.ly/muw8Ne117 Jun 2026 15:03 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3moiligkx2s2mhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3mlbqouilgn2vNow in @natchem.nature.com: Antibodies dominate drug development—but they’re big, costly, and can trigger immune reactions. #McGill professors Hanadi Sleiman & Maureen McKeague introduce Alenomers: barcoded aptamers with antibody‑level chemical diversity, screenable at massive scale buff.ly/BKKN4zS07 May 2026 17:32 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mlbqouilgn2vhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3mlbgjysili2r🧬#D2RProjectSpotlight: Switchable self-amplifying RNA: Safe, Selective, and Programmable Therapeutic Expression led by Prof. Maureen McKeague with collaborator Prof. Anna Blakney 🔗Learn more here: buff.ly/hlfhhvb07 May 2026 14:30 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mlbgjysili2rhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3ml4ggc44qz2v🧬#D2RProjectSpotlight: Targeting miRNAs in Embryonal Brain Tumors (@mcgillu Prof. Jacek Majewski) This project will study the molecular effects of this genome rearrangement and explore the use of microRNA inhibitors – sponges – to counteract the oncogenic changes buff.ly/309J3d205 May 2026 14:45 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3ml4ggc44qz2vhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3ml26db7kej2uD2R awards nearly $6M in funding to support 4 Translational Impact research projects focused on advancing RNA-based therapies for cancer and rare genetic diseases. 🔗 Learn more about these projects and the funded professors here: buff.ly/TPzPPdH04 May 2026 17:15 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3ml26db7kej2uhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3mk6ybucxia25And that's a wrap on Day 1 of the #D2RSymposium2026 🎉 All of today’s sessions highlighted that the research, both within the D2R community and beyond, is full of exciting developments. Stay tuned for even more on Day 2 tomorrow!23 Apr 2026 21:45 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mk6ybucxia25https://bsky.app/profile/d2rmcgill.bsky.social/post/3mk6nze6gvw2p#D2RSymposium2026 is underway! Sharing a few highlights from the action 📸 Tune into our LinkedIn for all the updates! 🧬 #RNATherapeutics23 Apr 2026 18:41 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mk6nze6gvw2phttps://bsky.app/profile/d2rmcgill.bsky.social/post/3mk63v5t2lw25🌟 The #D2RSymposium2026 is officially underway! Today and tomorrow we will be posting highlights of the event on our LinkedIn including inspiring talks, innovative research, trainee presentations, and more in #RNAtherapeutics.💡Big MERCI to all our sponsors! buff.ly/YzOWyGL https://www.mcgill.ca/dna-to-rna/events/d2r-research-symposium/research-symposium-2026/sponsors23 Apr 2026 13:16 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mk63v5t2lw25https://bsky.app/profile/d2rmcgill.bsky.social/post/3mhirxdn3vj2u🌟D2R is seeking a strategic and collaborative leader to join our team as Associate Director, Indigenous Health Research for D2R. This role supports Indigenous-led health research, fosters strong partnerships with Indigenous communities & organizations and more! Learn more: buff.ly/zxV3Uxx20 Mar 2026 15:02 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mhirxdn3vj2uhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3mgd3nqyo6o2l🔊 #D2RProjectSpotlight: D2R - Health Data Science (D2R-HeDS) platform 💡 Scientific Director: Guillaume Bourque (@McGillu) 🔗 Learn more: buff.ly/qDphDDy #RNA #RNATherapy #RNAResearch05 Mar 2026 15:15 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mgd3nqyo6o2lhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3mg64fjvcyl2a#D2RProjectSpotlight: End to end sequencing platform for RNA therapeutics quality control (EESPRNATQC) Scientific Director: Ioannis Ragoussis (@mcgillu)🔗 Learn more here: buff.ly/zhzGYc703 Mar 2026 15:45 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mg64fjvcyl2ahttps://bsky.app/profile/d2rmcgill.bsky.social/post/3mfmhhj74el2x🔊 #D2RProjectSpotlight: Centre for Applied Nanomedicine (CAN)💡 Scientific Director: Janusz Rak (RI-MUHC)🧬 Centre for Applied Nanomedicine (CAN) is a place/platform where specialized instruments measure, observe, and characterize myriads of small objects known as nanoparticles 🔗 buff.ly/Hv3NYJV24 Feb 2026 15:15 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mfmhhj74el2xhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3mfjzlqipda2l#BlackHistoryMonth D2R held a webinar on Anti-Black Racism in Health Research. It examined how slavery and anti-Black racism in Canada shaped inequities in health research & the systemic barriers that continue to influence scientific inquiry and health outcomes today. Watch here: buff.ly/uaYFjZA23 Feb 2026 16:01 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mfjzlqipda2lhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3mf7v4y23rb2h#D2RProjectSpotlight: RNA therapies for the treatment of a rare neurological disease led by Jo Anne Stratton (@mcgillu) This project aims to understand how RNA-based therapies can be optimized to target Schwann cells, the major cell type affected in Neurofibromatosis type 2.🔗 buff.ly/QYf2Kfg19 Feb 2026 15:15 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mf7v4y23rb2hhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3mf2tngv7ew2h🔊 #D2RProjectSpotlight: RNA therapeutics to block USP15-driven neuroinflammation in the brain led by Philippe Gros (@mcgillu) this project aims to test the capacity of these USP15 modalities to block neuroinflammation in vivo following delivery to the brain. Learn more: buff.ly/P0QfkgL17 Feb 2026 15:05 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mf2tngv7ew2hhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3meqrihljp427🔊 #D2RProjectSpotlight: mRNA Therapy to Prevent Liver Disease Progression in Zellweger Spectrum Disorder led by Nancy Braverman (@McGillu) ZSD is a rare genetic disorder, most patients harbor mutations in PEX1 gene. This project aims to restore PEX1 function. Learn more: buff.ly/3Y93ZQY13 Feb 2026 15:00 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3meqrihljp427https://bsky.app/profile/d2rmcgill.bsky.social/post/3mejad6liim2v🔊 #D2RProjectSpotlight: Aptamer-short hairpin RNA conjugation for gene therapy against HIV led by Anne Gatignol (Jewish General Hospital)🧬This research aims to support a more effective procedure in which a person's own cells are modified to make them resistant to HIV.🔗 buff.ly/WudYn1G10 Feb 2026 15:04 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mejad6liim2vhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3me76dwnjjp2q🔊 #D2RProjectSpotlight: Lipid Nanoparticles for Nasal mRNA Vaccines💡 Led by Larry Lands (RI-MUHC) 🧬 This project explores delivering RNA vaccines through a nose spray. This nasal method is not only more convenient but could offer better protection for the lungs. 🔗 Learn more: buff.ly/raSze2106 Feb 2026 15:02 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3me76dwnjjp2qhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3me27se5wxr2qOn #WorldCancerDay, we are reminded why research matters. D2R supports research across many types of #cancer, because whether they affect millions or thousands, every diagnosis deserves attention. #cancerresearch #cancerawareness #knowledgetocure04 Feb 2026 15:45 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3me27se5wxr2qhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3mdxoj4muqj2h🔊 #D2RProjectSpotlight: 3’UTR engineering for next-generation T cell mRNA therapeutics led by Thomas Duchaine (@mcgillu) This project aims to improve cancer immunotherapies by designing “smart” RNA switches that control how long therapeutic mRNAs stay active in immune cells. buff.ly/iyMZTzA03 Feb 2026 15:30 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mdxoj4muqj2hhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3mdl4kbqnyq2v🔊 #D2RProjectSpotlight: Development of RNA therapeutics against USP15-dependent neuroinflammation led by Philippe Gros, PhD🧬This project aims to develop inhibitors of USP15 which can dampen neuroinflammation using an RNA therapeutics approach. 🔗 Learn more: buff.ly/o3CRrRl29 Jan 2026 15:36 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mdl4kbqnyq2vhttps://bsky.app/profile/d2rmcgill.bsky.social/post/3mdg3cjdoqq25🔊 #D2RProjectSpotlight: Targeting MET exon 14 skipping variant in the early metastatic dissemination in lung cancer 🧬 Led by Morag Park (@mcgillgci.bsky.social) this project aims a novel therapy using targeted molecules designed to block this mutation. 🔗 buff.ly/VfPel6h27 Jan 2026 15:31 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mdg3cjdoqq25https://bsky.app/profile/d2rmcgill.bsky.social/post/3md46hzyeoe2a#D2RProjectSpotlight: Injectable Hydrogel/mRNA-LNP Platform for In Vivo CAR-T Cell Engineering 🧬Led by Guojun Chen (@McGillu) this project aims to accelerate the development of next-generation immunotherapies buff.ly/Xa2wnaT23 Jan 2026 17:01 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3md46hzyeoe2ahttps://bsky.app/profile/d2rmcgill.bsky.social/post/3mcujtlverb25#D2RProjectSpotlight: Transient CAR-T Cell engineering🧬Led by Taha Azad (@USherbrooke) this project aims to produce safe & effective CAR-Ts, and help accelerate RNA-based cell therapy development buff.ly/Tsz4eBD20 Jan 2026 16:03 +0000at://did:plc:fa4emyepagvyxa25ddl5eshx/app.bsky.feed.post/3mcujtlverb25